» Articles » PMID: 9950424

OPGL is a Key Regulator of Osteoclastogenesis, Lymphocyte Development and Lymph-node Organogenesis

Overview
Journal Nature
Specialty Science
Date 1999 Feb 9
PMID 9950424
Citations 1009
Authors
Affiliations
Soon will be listed here.
Abstract

The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.

Citing Articles

Osteoporosis and Rheumatoid Arthritis: Mechanisms Underlying Osteoclast Differentiation and Activation or Factors Associated with Hip Fractures.

Miyamoto T J Clin Med. 2025; 14(4).

PMID: 40004668 PMC: 11856638. DOI: 10.3390/jcm14041138.


Protective Effect of Methyl Sulfonyl Methane on the Progression of Age-Induced Bone Loss by Regulating Oxidative Stress-Mediated Bone Resorption.

Zhang D, Wang L, Tang L, Zhang Y, Zhang H, Zou L Antioxidants (Basel). 2025; 14(2).

PMID: 40002402 PMC: 11851857. DOI: 10.3390/antiox14020216.


Targeting osteoclast-derived DPP4 alleviates inflammation-mediated ectopic bone formation in ankylosing spondylitis.

Lee S, Lee K, Kim D, Jeon C, Whangbo M, Jo H Arthritis Res Ther. 2025; 27(1):40.

PMID: 40001226 PMC: 11853818. DOI: 10.1186/s13075-025-03474-2.


Deep-insights: Nanoengineered gel-based localized drug delivery for arthritis management.

Sriram A, Ithape H, Singh P Asian J Pharm Sci. 2025; 20(1):101012.

PMID: 39995751 PMC: 11848107. DOI: 10.1016/j.ajps.2024.101012.


T cell related osteoimmunology in fracture healing: Potential targets for augmenting bone regeneration.

Wang H, Li Y, Li H, Yan X, Jiang Z, Feng L J Orthop Translat. 2025; 51:82-93.

PMID: 39991456 PMC: 11847249. DOI: 10.1016/j.jot.2024.12.004.